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Africa has faced epidemics throughout its history, from
smallpox to recurrent epidemicsofmalaria, sleeping sickness,
and many other lethal diseases. The spread of HIV infection
across the continent, beginning in the 1980s, caused tens of
millions of deaths, and multiple localized outbreaks of Ebola
virus disease, most notably in West Africa in 2013–2016,
caused thousands of deaths and great suffering. Responses
to African epidemics have been challenged by limited in-
frastructure and fragile healthcare systems, including the lack
of adequate surveillance to assess the scope of the outbreak,
and inadequate systems for the prevention, diagnosis, and
management of disease. Yet Africa has also been the site of
key advances in infectious disease control, including case
containment and ring vaccination for smallpox; vector control
andmassdrugadministration for onchocerciasis,malaria, and
other vector-borne diseases; integrated community case
management for common illnesses; effective treatment to
facilitate prevention of HIV/AIDS and tuberculosis; and, most
recently, development of treatments and a vaccine against
Ebola virus disease. All countries, within Africa and beyond,
have benefited from these advances.
The novel coronavirus disease (COVID-19) pandemic
emerged in China in late 2019 and spread rapidly around the
world in early 2020. The first confirmed case of COVID-19 in
Africa was reported in Egypt on February 14 and the second a
day later in Algeria. By March, COVID-19 cases were being
reported across most of the continent. As with the rest of the
world, initial caseswere imported fromother regions, followed
by local transmission. By early April, nearly every country in
Africa reported COVID-19, with hundreds to thousands of
cases reported in the hardest-hit countries, presumably many
additional infections that were unidentified, and hundreds of
deaths from COVID-19 noted across the continent. While at
this writing the number of cases and deaths in Africa remains
relatively low, compared with other regions, numbers are in-
creasing steadily, and fears are mounting of a major humani-
tarian crisis as transmission accelerates.
Africa has reacted quickly to COVID-19. An emergency
meeting of African health ministers to discuss the pandemic
was hosted by the African Union Commission on February 22,
resulting in the rapid establishment of the Africa Taskforce for
Coronavirus Preparedness and Response by the African
UnionCommission, AfricaCDC, and theWHORegional Office
for Africa (AFRO), in partnershipwith African governments and
other stakeholders. Africa Taskforce for Coronavirus Pre-
paredness and Response identified and has worked diligently
to deliver on six work streams: laboratory diagnosis and
subtyping; surveillance, including screening at points of entry
andcross-border activities; infection prevention and control in
healthcare facilities; clinical management of severe COVID-
19; risk communication; and supply chain management and
stockpiles. The WHO has supported African countries in the
development of public health response plans and, with the
World Bank and other donors, established a global platform to
link plans to funding, facilitating transparency with regard to
financing of countries’ actions.
By March, governments and nongovernmental organiza-
tions announced programs to support global COVID-19
control and research. The Global Fund to Fight AIDS, Tuber-
culosis, and Malaria allowed recipients to use funds from
existing grants for efforts to control COVID-19. No-interest
loans for affected low-income countries were approved by the
International Monetary Fund. Resources to fight COVID-19
were freed from funds for control of Ebola virus disease after
abatement of an outbreak in the eastern Democratic Republic
of Congo. On March 27, the African Development Bank
launched a$3billion social bond to address the pandemic, the
largest bond ever issued by the bank. On April 7, the African
Union and Africa CDC launched the Africa COVID-19 Re-
sponse Fund, a public–private partnership with the AfroCham-
pions Initiative, to raise funds for transmission prevention,
medical responses, and socioeconomic support for vulnerable
populations.
As has been the case elsewhere, national responses to the
COVID-19 pandemic in Africa have varied. Initial responses,
when the reported number of cases was low, were often muted.
Over time, aggressive responses have been announced inmany
countries. In South Africa, an early and comprehensive program
for widespread testing appears to be “flattening the curve” and
may serve as a model for successful COVID-19 control. Never-
theless, formidable challenges remain in implementing response
measures that appear to have allowed some resource-rich
countries to gain the upper hand on COVID-19. What can Africa
and global partners do to confront COVID-19?
1. Community ownership and local action. As with all out-
breaks, large or small, community ownership and local
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action are imperative for success andmust be at the heart
of any response. Proper community engagement and
involvement of social scientists will be essential in
implementing local and universal solutions for urban and
rural areas of Africa.
2. Physical distancing. Although it is essential to maintain
physical distancing, novel solutions are needed for many
areas of Africa, taking note of social and cultural norms.
Stringent lockdowns and working from home may limit
viral transmission, as appears to have been the case in
some countries. However, lockdowns are unlikely to be
implementable in many African countries, where a sig-
nificant proportion of the population depends on per-
formingphysical labor for daily pay in acasheconomyand
where indoor plumbing, electricity, and Internet access are
not always available. In these circumstances, sheltering at
home may not be possible and may even enhance trans-
mission in often overcrowded households and in urban
slums. Informal urban settlements, refugee camps, and
camps for internally displaced persons present additional
challenges. Furthermore, in some areas with relatively little
transmission of SARS-CoV-2, enforcement of lockdowns
mayentail greater risk to thepopulation than the virus itself.
There have been reports of violent enforcement of lock-
downs, curfews, and travel bans, including deaths at the
hands of police—vivid reminders that aggressive physical
distancing can have unintended negative consequences.
Food insecurity may become a major concern if the pan-
demic is protracted. A Malawi high court and political
leaders in some other countries have suspended lock-
downs because of lack of adequate provision for the poor.
Africa, like all regions of the world, must look for solutions
that best protect against viral transmission but respect civil
liberties and the rule of law.
3. Enhanced hygiene. There is urgent need for aggressive
implementation of low-cost, rapidly implementable sani-
tarymeasures, including improved access to soap,water,
and hand sanitizer. Lessons can be learned from the
control of Ebola virus disease, in which sanitation stations
were established at the entry of virtually every office,
shop, and place of worship.
4. Laboratory testing. The diagnostic market needs to be
unlocked to ensure speedy and affordable access to di-
agnostics for Africa. African countries must have the in-
frastructure, including trained personnel, reagents, and
equipment, to enable widespread COVID-19 testing, in-
cluding molecular tests for acute diagnosis and seros-
urveys for surveillance to define infection patterns and
guide prevention efforts. Africa CDC and the WHO have
played an important role in providing testing equipment,
kits, and laboratory training. The African Union plans to
distribute one million COVID-19 test kits across the con-
tinent, but, as inmanyareasof theworld, a severe shortfall
remains.
5. Supply chain. The global supply chain is vital to provide
criticalmedical and laboratory supplies, including personal
protective equipment for healthcare workers, but is cur-
rently heavily fractured. This is especially problematic for
Africa, considering the continent’s limited manufacturing
capacity. There is need for reliable humanitarian aid corri-
dors and services to assure provision of essential supplies
until routinesupplychainscanbe renewed.Oneshort-term
solution may be harvesting Africa’s vast capacity for local
production of low-tech items, for example, production of
reusable face masks by local seamsters.
6. Enhanced patient care. With limited care services, pre-
vention must be the highest priority, but for those who fall
ill, African countries must provide the best possible care,
including isolation to prevent disease spread, and re-
spiratory support for those critically ill. Shortages of in-
tensive care unit beds and ventilators have been much
discussed in the United States and Europe, but this
conversation takes on a different tone for most of Africa.
The WHO estimates that, for 43 of the continent’s 55
countries, there are fewer than 5,000 available intensive
care unit beds, equating to about five beds per onemillion
people (compared with 4,000 beds per million in Europe).
At least 10 countries have no ventilators. Furthermore, in
most countries, there is a critical shortage of healthcare
workers trained in intensive care. Novel solutions to en-
able ventilation of ill patients in limited resource environ-
ments are desperately needed, possibly building on
recent efforts in pandemic-stretched high-income coun-
tries. Expanded use of supplemental oxygen, continuous
positive airway pressure, and prone positioning may
minimize the need for mechanical ventilation, although it
is important tomaintain vigilance in avoiding transmission
to healthcare workers with these procedures.
7. Risk communication. Effective communication advocating
measures such asphysical distancing,masks, and hygiene
is essential, and should take advantage of the social con-
nectedness of many African societies. Affordable local ra-
dio and television stations, traditional village announcers,
religious leaders, community relays, and social media
should be used for widespread public health messaging,
and in particular to counter the expected spread of rumor
and misinformation (which thrives in a communication
vacuum) and lack of participation by segments of the
population who do not perceive themselves to be at risk.
Existing networks may be used, for example, established
groups of people living with HIV.
8. Modeling. Mathematical models have been used around
the world to guide COVID-19 preparation and re-
sponse. Despite their limitations, these tools should
be rapidly extended to support African countries in the
same manner.
9. Maintenance of services for non–COVID-19 diseases.
Public healthmeasures to control the spreadofCOVID-19
must engender minimal disruption of standard care for
other infectious and noninfectious diseases. During the
West African outbreak, disruptions and transfers of re-
sources due to Ebola virus disease were estimated to
have resulted in thousands of excess maternal and infant
deaths and millions of untreated cases of malaria. A
similar pattern is looming in the response to COVID-19. In
late March 2020, because of the pandemic, UNICEF ac-
knowledged that temporary discontinuation of mass
vaccination campaignsmight benecessary. Although this
move may be prudent to limit viral transmission, it will
undoubtedly lead to excess casesof vaccine-preventable
diseases. UNICEF urged prompt resumption of immuni-
zation activities as soon as is possible. Consistent with
UNICEF guidance, routine immunization services should
be a high priority, even in the setting of lockdowns.
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Maintenance of maternal child health and surgical ser-
vices is clearly at risk. Similarly at risk are management of
chronic infections that require regular chemotherapy,
notably HIV infection and tuberculosis, and acute infec-
tions that require rapid treatment, in particular malaria.
Systems for the prevention and treatment of many other
tropical infections, such as schistosomiasis, filarial infec-
tions, trypanosomiasis, and measles, are fragile, and may
be seriously disrupted. Noncommunicable diseases are
increasing across the continent, and maintaining surveil-
lance for andmanagement of hypertension, heart disease,
diabetes, cancer, and other diseases will be challenged.
Ironically, many chronic noninfectious diseases for which
management is challenged by the pandemic are risk fac-
tors for poor outcomes in COVID-19. Considering that the
risk of severe and fatal disease is highest in the elderly, the
young population structure of most African countries may
be an advantage. Whether this advantage will be coun-
terbalanced by inadequately managed comorbidities re-
mains to be seen; continued attention to controlling these
comorbidities, including chronic infectious and non-
infectious diseases, is a high priority.
10. Therapeutics and vaccines. As everywhere in the world,
decisions onprevention andmanagement ofCOVID-19 in
Africa must be evidence based. For example, use of
chloroquine, a common antimalarial that has been readily
available in Africa for decades and which has been ad-
vocated as a treatment for COVID-19 by politicians and
other nonexperts, should be limited to clinical trials until
efficacy and safety are better characterized. Despite this
recommendation, use of chloroquine and its analog
hydroxychloroquine for COVID-19 treatment and pre-
ventionwill likely occur, as in other parts of theworld, with
attendant risks of shortages of the drugs for appropriate
indications (non-falciparum malaria and rheumatologic
diseases) and of flooding markets with fake and sub-
standard medicines. Ill-informed comments suggesting
Africa as the location for COVID-19 vaccine testing have
unfortunately stirred up resistance to all vaccines. Gov-
ernments and policy-leaders on the continent should
continue to adhere to WHO guiding principles for immu-
nization during the pandemic.
11. Equitable access. It is essential that any therapeutics,
vaccines, and diagnostic assays validated through rig-
orous scientific study are made available in Africa. In the
long term, this will require increases in manufacturing
capacity in Africa, but in the short term, it will depend on
establishing ethical and legal frameworks of inclusion.
Provisions for equitable access and pricing, facilitated by
advances with other diseases such as HIV infection, will
need to be addressed. Within African countries, equity
requires attention to the most vulnerable members of
society, in particular mothers and young children.
12. Research. Research on the epidemiology, pathogene-
sis, genetics, prevention, diagnosis, andmanagement of
COVID-19 in the African context will be important to
provide guidance for ongoing approaches to the pan-
demic. The leadership of African CDC, the WHO/AFRO,
the African Academy of Sciences, the National Acade-
mies of Sciences, African Ministries of Health and Min-
istries of Scientific Research, and other partners in
developing research priorities and protocols will be
critical to advancing research on COVID-19 to best
guide future policies. Adapting and applying the WHO
Research and Development Blueprint for COVID-19 to
the African context is a logical place to start, with the
potential corollary benefit of long-term enhancement of
research infrastructure on the continent.
13. Addressing the economic impact. Beyond medical
consequences, COVID-19 will have a profound eco-
nomic impact on Africa, a continent much less prepared
to absorb economic downturns than wealthier regions
that have to date primarily borne the brunt of the pan-
demic. The African Development Bank recently esti-
mated that COVID-19 may cost Africa tens of billions of
dollars in gross domestic product, increases in national
budget deficits of 3–5%, and overall increases in public
debt of more than $100 billion. The African Union esti-
mates the loss of 20 million jobs on the continent. Over
the course of the pandemic, African countries already
suffering from resource limitations must address the
same economic challenges engaging the entire world,
with loss of income most threatening to the most vul-
nerablemembers of society.Wemust avoid the initiation
of a vicious cycle, with viral infections feeding economic
and societal disruption, which feed additional viral
infections.
Novel coronavirus disease presents unique and grave
challenges for Africa, as it has for the rest of the world. In-
frastructure and resource constraints make COVID-19 an
even more threatening disease for Africa than for many of the
resource-rich countries that it has already devastated. How-
ever, multiple African countries and organizations have dem-
onstrated leadership in elaborating systems for the prevention
of COVID-19 and in planning for optimal research strategies in
the African context. Key public health, clinical, and research
goals to mitigate the impact of COVID-19 can be achieved.
Ideally, progress toward the mitigation of COVID-19 will lead
to long-term improvements in African health and research
systems. But, in the short term, much additional support from
international andAfrican sources is needed to preventCOVID-
19 frombecoming an increasing health andeconomic disaster
in Africa.
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